Tony Berberabe, MPH

Articles

Signature Trial Program Aims for Rapid Delivery of Novel Therapies

August 4th 2016

A collection of clinical trials that uses a target-specific and tissue-agnostic algorithm to rapidly match patients to investigational therapies aimed at the tumor's molecular makeup takes the approach that "one trial really does not fit all."

With Its Long History and Pioneering Spirit, Urology of Virginia Faces a Changing Landscape

July 31st 2016

Michael Fabrizio, MD, and Dana Adams, COO, provide their perspective on the challenges that urology practices face today.

Galeterone Prostate Cancer Trial Closes as PFS Rates Miss Mark

July 26th 2016

The pivotal phase III trial ARMOR 3-SV will be discontinued based on recommendations made by the trial's independent data monitoring committee.

Capmatinib Trial Targets New Molecular Subsets of Patients in NSCLC

July 4th 2016

An ongoing phase II, four-cohort trial involving capmatinib (INC280), an oral MET inhibitor, will determine the clinical activity of the agent in pretreated patients with advanced non-small cell lung cancer who have undergone one or two lines of therapy.

Second-Generation AR-Targeting Agent Explored in High-Risk Prostate Cancer

June 15th 2016

Researchers are hoping the results of a late-stage efficacy and safety study of apalutamide in patients with high-risk, localized, or locally advanced prostate cancer who are receiving primary radiation therapy will demonstrate an improvement in metastasis-free survival.

Atezolizumab Effective in First-Line Setting in Bladder Cancer

June 6th 2016

Patients with metastatic urothelial carcinoma who were ineligible for standard cisplatin-based chemotherapy achieved a 24% reduction in tumor size and had a median survival of 14.8 months after taking the immunotherapy agent atezolizumab (Tecentriq).

Temozolomide Trial Shows Improved 5-Year Survival Rates in Anaplastic Glioma

June 4th 2016

Results from a phase III trial investigating the benefit of adjuvant temozolomide in combination with radiation therapy has the potential to be practice changing for a rare type of brain cancer.

Finalists Revealed for the 2016 Giants of Cancer Care Awards

June 3rd 2016

An elite group of finalists have been recognized for their achievements, talent, and the compassionate care they provide to their patients and families in the 2016 Giants of Cancer Care® recognition program.

FDA Approves Radioactive Imaging Agent Axumin in Recurrent Prostate Cancer

May 27th 2016

The radioactive imaging agent, fluciclovine F18 (Axumin), was approved by the FDA for use in positron emission tomography scans in men with suspected recurrence of prostate cancer whose prostate-specific antigen levels rise following prior treatment.

Gene Expression Signature Predicts Hormonal Resistance in Prostate Cancer

May 24th 2016

Using the Decipher Prostate Cancer Classifier assay to predict which patients might respond to hormonal therapy has resulted in the discovery and validation of an adjuvant androgen-deprivation therapy resistance signature.

High Genomic Classifier Score Increases Risk of Dying From Prostate Cancer

May 21st 2016

Results from a study using the Decipher Prostate Cancer Classifier noted that its use added very strong data about the likelihood of patients with prostate cancer dying within 10 years.

ERBB Alteration Linked to Improved PFS With Afatinib in Urothelial Cancer

May 5th 2016

Five of 6 patients with metastatic urothelial cancer and at least 1 of 2 genetic alterations demonstrated a marked improvement in 3-month progression free survival of 6.6 months when given afatinib (Gilotrif), compared with patients who lacked these specific genetic abnormalities.

Acalabrutinib Challenges Ibrutinib in High-Risk CLL Trial

April 22nd 2016

Patients with relapsed chronic lymphocytic leukemia face a difficult treatment journey, but a phase III safety and efficacy trial involving the second-generation Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) will help inform oncologists about whether the emerging agent can offer a greater benefit to patients with high-risk disease over ibrutinib (Imbruvica).

Partner's Buy-In Key to Minneapolis Urology Group's Success

April 10th 2016

At Metro Urology of Minneapolis, urologists are at the forefront of introducing new techniques and technology, especially with respect to advanced prostate cancer care.

Novel Entrectinib Trial Focuses on Gene Rearrangements Across Many Tumor Types

March 30th 2016

Researchers have designed a recently launched clinical study into entrectinib, a first-in-class inhibitor of tropomyosin receptor kinases, as a basket trial in which the drug can be evaluated simultaneously for activity against three gene alterations and multiple tumor types.

Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF Pathways

March 29th 2016

Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.

Questions Loom Over Androgen-Targeting Strategies in Metastatic Prostate Cancer

March 22nd 2016

Targeting androgen receptor signaling with recently approved agents has improved outcomes for men with metastatic castration-resistant prostate cancer but significant questions linger about how to tackle resistance to the therapies.

Quality of Life Scores Similar in Men Undergoing Active Surveillance Versus Those Without Prostate Cancer

March 14th 2016

Men with low-risk prostate cancer who chose active surveillance (AS) reported a higher quality of life than men who chose direct active treatment such as surgery or radiation.

Pancreatic Cancer Vaccine Makes Progress in Two Late-Stage Trials

March 10th 2016

The novel therapeutic vaccine algenpantucel-L, which is genetically engineered from human cell lines, is being evaluated in two phase III trials in patients with resected pancreatic cancer (IMPRESS) and borderline resectable or locally advanced unresectable pancreatic cancer (PILLAR).

Secondary Cancers Linked to Radiotherapy in Men With Prostate Cancer

March 9th 2016

Men with prostate cancer treated with radiotherapy were at higher risk for developing second malignancies in the bladder, colon, and rectum compared with men who were not exposed to radiotherapy.